AR085198A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
AR085198A1
AR085198A1 ARP110103735A ARP110103735A AR085198A1 AR 085198 A1 AR085198 A1 AR 085198A1 AR P110103735 A ARP110103735 A AR P110103735A AR P110103735 A ARP110103735 A AR P110103735A AR 085198 A1 AR085198 A1 AR 085198A1
Authority
AR
Argentina
Prior art keywords
tau
phosphorylated
ser
phosphorylated ser
therapeutic
Prior art date
Application number
ARP110103735A
Other languages
English (en)
Original Assignee
Ac Inmune S A
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44947048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Inmune S A, Univ Leuven Kath filed Critical Ac Inmune S A
Publication of AR085198A1 publication Critical patent/AR085198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)

Abstract

La presente solicitud se refiere a métodos y composiciones para el uso terapéutico y de diagnóstico en el tratamiento de enfermedades y trastornos que son causados por ovillos neurofibrilares o están asociados con ellos. En particular, la solicitud se refiere a anticuerpos, para el uso terapéutico y diagnóstico en el tratamiento de tauopatías entre las que encuentra la enfermedad de Alzheimer (EA). Reivindicación 18: El anticuerpo de acuerdo con cualquiera de las reivindicaciones precedentes o uno de sus fragmentos funcionales, en donde dicho anticuerpo o fragmento de anticuerpo se une con un epítope seleccionado del grupo que consiste en Tau aa 15 - 20 que comprende una Tyr fosforilada en la posición 18 (Y18), Tau aa 405 - 412 que comprende una Ser fosforilada en la posición 409 (pS409), Tau aa 405 - 411 que comprende una Ser fosforitada en la posición 409 (pS409); Tau aa 208 - 218 que comprende una Thr fosforilada en la posición 212 (pT212) y una Ser fosforilada en la posición (pS214); Tau aa 393 - 401 que comprende una Ser fosforilada en la posición 396 (pS396), Tau aa 396 - 401 que comprende una Ser fosforilada en la posición 396 (pS396), Tau aa 394 - 400 que comprende una Ser fosforilada en la posición 396 (pS396), Tau aa 402 - 406 que comprende una Ser fosforilada en la posición 404 (pS404), y Tau aa 393 - 400 que comprende una Ser fosforilada en la posición 396 (pS396).
ARP110103735A 2010-10-07 2011-10-11 Composicion farmaceutica AR085198A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186810 2010-10-07
EP11174248 2011-07-15

Publications (1)

Publication Number Publication Date
AR085198A1 true AR085198A1 (es) 2013-09-18

Family

ID=44947048

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103735A AR085198A1 (es) 2010-10-07 2011-10-11 Composicion farmaceutica

Country Status (28)

Country Link
US (2) US9304138B2 (es)
EP (2) EP2625198B1 (es)
JP (2) JP6371526B2 (es)
KR (1) KR101988672B1 (es)
CN (1) CN103502272B (es)
AR (1) AR085198A1 (es)
AU (1) AU2011311516B2 (es)
BR (1) BR112013008333B1 (es)
CA (1) CA2812865C (es)
CL (1) CL2013000951A1 (es)
CO (1) CO6710903A2 (es)
CR (1) CR20130160A (es)
DK (1) DK2625198T3 (es)
EC (1) ECSP13012609A (es)
ES (1) ES2548686T3 (es)
HK (2) HK1187928A1 (es)
HU (1) HUE027649T2 (es)
IL (1) IL225568A (es)
MX (1) MX338421B (es)
MY (1) MY164376A (es)
PE (1) PE20140218A1 (es)
PL (1) PL2625198T3 (es)
RU (1) RU2603078C2 (es)
SG (1) SG189136A1 (es)
SI (1) SI2625198T1 (es)
TW (1) TW201216985A (es)
WO (1) WO2012045882A2 (es)
ZA (1) ZA201302432B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266585B2 (en) * 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
KR101988672B1 (ko) * 2010-10-07 2019-06-12 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
EP2670434B1 (en) 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
KR101991681B1 (ko) * 2011-12-20 2019-06-21 얀센 바이오테크 인코포레이티드 항-phf-타우 항체 및 그의 용도
EP2834270B1 (en) * 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
KR20150036346A (ko) * 2012-07-03 2015-04-07 워싱턴 유니버시티 Tau에 대한 항체
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
WO2014043480A1 (en) 2012-09-13 2014-03-20 Crystal Ronald G Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
SI2935326T1 (sl) * 2012-12-21 2021-03-31 Biogen Ma Inc. Človeška protitelesa ANTI-TAU
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
KR102233349B1 (ko) * 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
MX2016006356A (es) * 2013-11-27 2016-10-28 Ipierian Inc Metodos de tratamiento de una tauopatia.
BR112016013562A2 (pt) 2013-12-20 2017-10-03 Hoffmann La Roche Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
EP3104870A4 (en) * 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
RU2730668C2 (ru) * 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
DK3303386T3 (da) 2015-06-05 2024-10-28 Genentech Inc Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EP3334761B1 (en) * 2015-08-13 2023-07-19 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
HUE053679T2 (hu) * 2016-07-12 2021-07-28 H Lundbeck As Hiperfoszforilezett TAU-ra specifikus antitestek és eljárások ezek alkalmazására
CN109562167A (zh) 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
AU2017373889A1 (en) * 2016-12-07 2019-06-06 Ac Immune Sa Anti-Tau antibodies and methods of use
EP3565836A1 (en) * 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018217630A1 (en) * 2017-05-21 2018-11-29 University Of Tennessee Research Foundation Methods and compositions for targeting tissue lesions
WO2019077500A1 (en) 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. ANTI-WATER ANTIBODIES AND USES THEREOF
CN111698937A (zh) * 2017-11-28 2020-09-22 国立大学法人三重大学 检测方法
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
WO2020073917A1 (en) * 2018-10-09 2020-04-16 Single Cell Technology, Inc. Anti-bcma antibodies
US20210347869A1 (en) * 2018-10-17 2021-11-11 The University Of Queensland Methods and compositions for treating tauopathies
US12016885B2 (en) 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
MX2021012488A (es) * 2019-04-12 2021-11-12 Phanes Therapeutics Inc Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos.
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN112752251B (zh) * 2019-10-29 2022-05-06 中国移动通信有限公司研究院 一种ue标识符的分配方法、装置和计算机可读存储介质
CN115066610A (zh) * 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法
PE20230840A1 (es) 2020-06-25 2023-05-19 Merck Sharp And Dohme Llc Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
US20240059766A1 (en) * 2020-12-16 2024-02-22 Voyager Therapeutics, Inc. Tau binding compounds
EP4014997A1 (en) 2020-12-16 2022-06-22 Consejo Superior de Investigaciones Científicas (CSIC) Stard1 inhibitors for the treatment of lysosomal disorders
IL305666A (en) * 2021-03-18 2023-11-01 Seagen Inc Anti-ALPP/ALPPL2 antibodies and antibody-drug conjugates
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP2009104A1 (en) 1991-12-06 2008-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease
CA2141216A1 (en) 1992-07-27 1994-02-03 Michael J. Micklus Targeting of liposomes to the blood-brain barrier
ES2176342T5 (es) 1994-10-21 2010-02-09 Innogenetics N.V. Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos.
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
JP2004503747A (ja) * 2000-07-11 2004-02-05 モレキュラー　ジェリアトリクス　コーポレイション 結合物質の同定するための試薬と方法
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003302676A1 (en) 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
US20060135403A1 (en) 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US7780963B2 (en) 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
US9555032B2 (en) 2007-06-13 2017-01-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
SG185316A1 (en) * 2007-10-19 2012-11-29 Immunas Pharma Inc ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CN102596221B (zh) * 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
PE20120817A1 (es) * 2009-07-30 2012-07-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos
KR101988672B1 (ko) * 2010-10-07 2019-06-12 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체

Also Published As

Publication number Publication date
TW201216985A (en) 2012-05-01
CR20130160A (es) 2013-09-03
IL225568A (en) 2017-06-29
CA2812865C (en) 2021-01-26
SI2625198T1 (sl) 2015-11-30
EP2987807A3 (en) 2016-06-01
CO6710903A2 (es) 2013-07-15
MX2013003800A (es) 2013-06-28
EP2625198A2 (en) 2013-08-14
ES2548686T3 (es) 2015-10-20
US10100104B2 (en) 2018-10-16
US9304138B2 (en) 2016-04-05
RU2013120544A (ru) 2014-11-20
HK1216897A1 (zh) 2016-12-09
AU2011311516B2 (en) 2015-06-11
BR112013008333B1 (pt) 2022-10-11
CN103502272B (zh) 2016-06-15
HUE027649T2 (en) 2016-10-28
US20160304590A1 (en) 2016-10-20
MY164376A (en) 2017-12-15
EP2625198B1 (en) 2015-07-22
ZA201302432B (en) 2016-07-27
PL2625198T3 (pl) 2015-12-31
HK1187928A1 (zh) 2014-04-17
EP2987807A2 (en) 2016-02-24
KR20130115279A (ko) 2013-10-21
AU2011311516A1 (en) 2013-04-18
JP6371526B2 (ja) 2018-08-08
KR101988672B1 (ko) 2019-06-12
PE20140218A1 (es) 2014-03-01
JP2017113004A (ja) 2017-06-29
JP2014502141A (ja) 2014-01-30
WO2012045882A2 (en) 2012-04-12
MX338421B (es) 2016-04-15
IL225568A0 (en) 2013-06-27
ECSP13012609A (es) 2013-07-31
CA2812865A1 (en) 2012-04-12
DK2625198T3 (en) 2015-09-28
RU2603078C2 (ru) 2016-11-20
WO2012045882A3 (en) 2012-05-31
BR112013008333A2 (pt) 2021-09-21
CN103502272A (zh) 2014-01-08
US20120276009A1 (en) 2012-11-01
SG189136A1 (en) 2013-05-31
CL2013000951A1 (es) 2014-01-03

Similar Documents

Publication Publication Date Title
AR085198A1 (es) Composicion farmaceutica
CO2018014325A2 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
CL2016000215A1 (es) Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).
CL2019003000A1 (es) Proteínas de unión a antígenos trem2 y usos de estas.
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
AR092818A1 (es) Anticuerpo tau humanizado
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
CO2017012974A2 (es) Anticuerpos de unión a tau
ECSP11011367A (es) Composición farmacéutica
PE20190440A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
CO2017012971A2 (es) Anticuerpos de unión a tau
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
AR084627A1 (es) Formulacion farmaceutica que comprende una droga biofarmaceutica
BR112019008417A2 (pt) compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y
EA033433B1 (ru) Антитела к tau и их применение
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CY1118046T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
MA38161A1 (fr) Anticorps anti-bmp-6
BR112015018035A2 (pt) anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
CU20200015A7 (es) Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha

Legal Events

Date Code Title Description
FB Suspension of granting procedure